CTOs on the Move

Immunovant

www.immunovant.com

 
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.immunovant.com
  • 320 West 37th Street 5th Floor
    New York, NY USA 10018
  • Phone: 212.847.6204

Executives

Name Title Contact Details

Similar Companies

Eccrine Systems

Eccrine Systems, Inc., is focused on the development of non-invasive disposable electronic patches that accurately measure and transmit real-time data about human sweat. Applications for our technology and IP span market opportunities within medicine, industry, and sports. We seek to establish exclusive collaborations with downstream partners who understand the opportunity for embedding and deploying our technology in their market-specific applications. Our role in these collaborations is the modular development and prototyping of desired sweat sensor features and capabilities. Our partners embed our technology in their commercial applications and translate data about sweat and other biometrics into high value products for their customers.

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.

Stuart Therapeutics

Stuart Therapeutics was established in 2017 for the development and commercialization of PolyCol, a versatile therapeutic platform that offers a unique tissue reparative approach to a variety of ophthalmic disease indications.

Synosia Therapeutics

Synosia Therapeutics is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.